Enliven therapeutics to share initial proof of concept data from phase 1 clinical trial of elvn-001 and host virtual key opinion leader event on april 11, 2024

Boulder, colo., march 28, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on thursday, april 11, 2024, at 8:00 a.m. et to discuss initial proof of concept data on elvn-001 and the evolving chronic myeloid leukemia (cml) landscape. elvn-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the atp-pocket of the bcr-abl gene fusion, the oncogenic driver for patients with cml.
ELVN Ratings Summary
ELVN Quant Ranking